Shenzhen Kangtai Biological Products (300601) Stock Overview
Shenzhen Kangtai Biological Products Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
300601 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Shenzhen Kangtai Biological Products Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥14.83 |
| 52 Week High | CN¥21.12 |
| 52 Week Low | CN¥13.10 |
| Beta | 1.1 |
| 1 Month Change | -15.01% |
| 3 Month Change | -16.59% |
| 1 Year Change | -18.56% |
| 3 Year Change | -51.85% |
| 5 Year Change | -85.62% |
| Change since IPO | 649.62% |
Recent News & Updates
Recent updates
Does Shenzhen Kangtai Biological Products (SZSE:300601) Have A Healthy Balance Sheet?
Feb 14
Market Cool On Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Earnings
Jan 17Investors Appear Satisfied With Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Prospects As Shares Rocket 32%
Oct 13Here's Why Shenzhen Kangtai Biological Products (SZSE:300601) Has A Meaningful Debt Burden
Sep 25These Analysts Just Made A Massive Downgrade To Their Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601) EPS Forecasts
Sep 02Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Share Price Not Quite Adding Up
Aug 13Shenzhen Kangtai Biological Products (SZSE:300601) Seems To Use Debt Quite Sensibly
May 25Shenzhen Kangtai Biological Products' (SZSE:300601) Promising Earnings May Rest On Soft Foundations
May 03Earnings Report: Shenzhen Kangtai Biological Products Co., Ltd. Missed Revenue Estimates By 49%
May 01Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Share Price Matching Investor Opinion
Feb 27Shareholder Returns
| 300601 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -3.7% | -3.0% | -1.3% |
| 1Y | -18.6% | 0.8% | 17.1% |
Return vs Industry: 300601 underperformed the CN Biotechs industry which returned 0.8% over the past year.
Return vs Market: 300601 underperformed the CN Market which returned 17.1% over the past year.
Price Volatility
| 300601 volatility | |
|---|---|
| 300601 Average Weekly Movement | 3.0% |
| Biotechs Industry Average Movement | 4.1% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in CN Market | 9.1% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 300601 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300601's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,913 | Xiang Miao | www.biokangtai.com |
Shenzhen Kangtai Biological Products Co., Ltd. researches and develops, produces, and sells various types of human vaccines in China. The company’s marketed vaccines include 13-valent pneumococcal polysaccharide conjugate vaccine, varicella vaccine, freeze-dried, hepatitis B vaccine, inflammatory vaccine, 23-valent pneumococcal polysaccharide vaccine, DTAP/HIB combined vaccine, diphtheria, tetanus and acellular pertussis combined vaccine, adsorbed, rabies vaccine (human diploid cell) for human use, hib conjugate vaccine, measles and rubella combined vaccine, sars-cov-2 vaccine, inactivated, and covid-19 vaccine.
Shenzhen Kangtai Biological Products Co., Ltd. Fundamentals Summary
| 300601 fundamental statistics | |
|---|---|
| Market cap | CN¥16.56b |
| Earnings (TTM) | -CN¥100.29m |
| Revenue (TTM) | CN¥2.70b |
Is 300601 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300601 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.70b |
| Cost of Revenue | CN¥906.94m |
| Gross Profit | CN¥1.79b |
| Other Expenses | CN¥1.89b |
| Earnings | -CN¥100.29m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.09 |
| Gross Margin | 66.37% |
| Net Profit Margin | -3.72% |
| Debt/Equity Ratio | 19.5% |
How did 300601 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/16 18:37 |
| End of Day Share Price | 2025/12/16 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shenzhen Kangtai Biological Products Co., Ltd. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Bing Zhao | China Renaissance Securities |
| Zhu Chen | Citic Securities Co., Ltd. |